Femasys gets CE mark for FemBloc delivery system in Europe, polymer approval expected mid-2025

FEMASYS INC

FemBloc delivery system receives first-in-world CE mark certification under EU MDR for non-surgical permanent birth control.
FemBloc blended polymer completes G12 Special MDR Audit; Notified Body recommends CE mark pending EMA review, approval expected mid-2025.
Company continues enrolling participants in FDA IDE-approved pivotal clinical trial for U.S. approval of FemBloc.
CEO Kathy Lee-Sepsick highlights FemBloc as a safer, accessible alternative to surgical sterilization, the only option today.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.